Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

Published:2014-01-14 Issue:4 Volume:53 Page:295-304
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Scheen André J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-013-0128-8.pdf

Reference52 articles.

1. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents: a guide to selection. Drugs. 1998;55(2):225–36.

2. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385–411.

3. Scheen AJ, Lefèbvre PJ. Antihyperglycemic agents: drug interactions of clinical importance. Drug Saf. 1995;12(1):32–45.

4. Scheen AJ, Demagalhaes A, Salvatore T, et al. Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur J Clin Investig. 1994;24:50–4.

5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–96.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry Reports;2024-08

2. Effects of SGLT2-inhibitor on The Expression of MicroRNA-21, Transforming Growth Factor-β1, and Matrix Metalloproteinase-2 in The Process of Cardiac Fibrosis in Hyperglycemic Model Rats;The Indonesian Biomedical Journal;2024-02-23

3. Development of a highly sensitive and eco-friendly high-performance thin-layer chromatography approach for the determination of empagliflozin, pioglitazone, and rosuvastatin simultaneously in pharmaceutical preparations and different biological fluids;JPC – Journal of Planar Chromatography – Modern TLC;2023-12-21

4. Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis;British Journal of Clinical Pharmacology;2023-03-28

5. The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus;Life;2023-03-20